Heron Therapeutics, Inc.
Heron Therapeutics, Inc. (HRTX) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
hrtx · stock forecast · 19 analysts (3M) · FMP · updated Jun 9, 2026
Analyst Rating & Consensus
Based on 19 Wall Street analysts in the past 3 months
Buy
19 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$9.00
Consensus
$6.67
+1370.5% upside
Low
$5.00
Median: $6 · Last Close: $0.45
12-Month Price Target Forecast
Historical closing prices + analyst 12-month price target forecast cone
Short-Term Price Prediction
Low ActivityAlgorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-10 | $0.45 | ↑ 0.00% |
1-day model range: $0.44–$0.47. Peak: $0.47 (+0.00%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Insufficient Trading Activity — Sentiment Signals Disabled
This stock has very low trading volume (ZOMBIE condition). Sentiment analysis requires sufficient price action. RSI and MACD values below are still shown for reference.
Moving Averages · HRTX · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-06-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2026-06-03 | Needham | Downgrade ↓ | Buy→Hold |
| 2026-01-09 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-08-08 | Needham | Maintains | Buy→Buy |
| 2025-04-11 | Needham | Maintains | Buy→Buy |
| 2025-02-28 | Needham | Maintains | Buy→Buy |
| 2024-12-04 | Needham | Maintains | Buy→Buy |
| 2024-11-13 | Needham | Maintains | Buy→Buy |
| 2024-09-25 | Needham | Maintains | Buy→Buy |
| 2024-08-07 | Needham | Maintains | Buy→Buy |
Wall Street analysts have recently issued updated ratings on Heron Therapeutics, Inc. (HRTX) stock. Of the recent 55 rating actions, 0 were upgrades and 2 were downgrades. 19 analysts currently cover HRTX.
Analyst Recommendation Trends
HRTX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 1 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$168M
↓ 16.9% YoY
Revenue Next Year
$176M
↑ 4.6% YoY
EPS This Year
$-0.05
EPS Next Year
$-0.01
↓ 81.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast HRTX EPS of $-0.05 for the current fiscal year, based on estimates from 1 analysts. The HRTX revenue forecast is $168M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The HRTX stock forecast is supported by two independent data sources: analyst consensus ratings from 19 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus HRTX price target is $6.67 (+1370.5% upside), with an analyst consensus of Buy.
The HRTX short-term stock prediction for tomorrow is $0.45 (+0.00%).
Heron Therapeutics, Inc. trades on NASDAQ under the ticker HRTX. The HRTX stock outlook for 2027 is broadly positive, supported by a Buy consensus among 95% of covering analysts.
Frequently asked questions
HRTX forecast · 8 questionsAccording to 19 Wall Street analysts, the average 12-month HRTX price target is $6.67, with a high forecast of $9.00 and a low of $5.00. The median price target is shown in the chart above when available. This implies +1370.5% potential upside from the current price of $0.45.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.